Androgen deprivation therapy survival

Academia.edu is a platform for academics to share research papers.

After the cessation of androgen deprivation therapy (ADT), serum testosterone (T) levels usually recover from castrate levels to normal levels. However, some patients maintain the castrate T levels for several years after cessation, especially if hormonal manipulation is used for prolonged periods. / Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer : A Southwest Oncology Group report. In: Journal of Clinical Oncology. 1994 ; Vol. 12, No. 9. pp. 1868-1875.

Androgen deprivation therapy (ADT) or combined with first-generation anti-androgen drugs such as bicalutamide and flutamide have been chosen as first line for hormone naïve metastatic prostate cancer. Apr 24, 2013 · In this paper, Bennett et al. [1] report the effects of an anti-androgen drug on autophagy and the subsequent impact on response to androgen-deprivation therapy alone or combined with exiting chemotherapeutic treatments. Feb 14, 2019 · Bayer's investigational drug darolutamide plus androgen deprivation therapy (ADT) significantly extends metastasis-free survival compared to placebo plus ADT in non-metastatic castration-resistant prostate cancer - read this article along with other careers information, tips and advice on BioSpace However, survival in men with metastatic hormone-sensitive prostate cancer may be shorter when androgen deprivation therapy is given intermittently rather than continuously, according to a large study of 770 men treated with intermittent therapy and 765 men treated with continuous therapy, who were followed for a median of almost 10 years ...

Objective. To examine duration of use and survival rates of Australian males who initiated androgen deprivation therapy for prostate cancer, including survival rates stratified by the type of the initial androgen deprivation therapy and age at initiation. Background. Loss of bone mineral density is an unintended consequence of androgen deprivation therapy in men with prostate cancer. Supplementation with calcium and/or vitamin D in these men seems logical and is advocated by many lay and professional groups. Apr 30, 2014 · The representative guidelines do not recommend androgen deprivation therapy (ADT) as a primary treatment for localized prostate cancer. However, in clinical practice, the use of primary ADT for localized prostate cancer has been widespread, especially among older patients.